Search

Smith & Nephew PLC

Gesloten

1,215 1.21

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1202

Max

1229.5

Belangrijke statistieken

By Trading Economics

Inkomsten

296M

Verkoop

3B

K/W

Sectorgemiddelde

29.702

22.558

EPS

0.429

Dividendrendement

3.04

Winstmarge

9.895

Werknemers

17,000

EBITDA

723M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+18.63% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.04%

4.45%

Volgende Winsten

2 mrt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.6B

11B

Vorige openingsprijs

1213.79

Vorige sluitingsprijs

1215

Smith & Nephew PLC Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

20 jan 2026, 23:43 UTC

Marktinformatie

Gold Consolidates; May Face Technical Correction -- Market Talk

20 jan 2026, 23:42 UTC

Marktinformatie

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

20 jan 2026, 23:41 UTC

Winsten

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

20 jan 2026, 23:29 UTC

Marktinformatie

RBA Rate Hike in February Would Be a Painful One -- Market Talk

20 jan 2026, 23:26 UTC

Marktinformatie

Global Equities Roundup: Market Talk

20 jan 2026, 23:26 UTC

Marktinformatie

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

20 jan 2026, 22:45 UTC

Acquisities, Fusies, Overnames

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

20 jan 2026, 22:45 UTC

Acquisities, Fusies, Overnames

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

20 jan 2026, 22:44 UTC

Acquisities, Fusies, Overnames

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

20 jan 2026, 22:44 UTC

Acquisities, Fusies, Overnames

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

20 jan 2026, 22:43 UTC

Acquisities, Fusies, Overnames

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

20 jan 2026, 22:43 UTC

Acquisities, Fusies, Overnames

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

20 jan 2026, 22:27 UTC

Acquisities, Fusies, Overnames

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

20 jan 2026, 22:25 UTC

Acquisities, Fusies, Overnames

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

20 jan 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

20 jan 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

20 jan 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

20 jan 2026, 22:18 UTC

Winsten

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

20 jan 2026, 22:17 UTC

Acquisities, Fusies, Overnames

Netflix's Live Events Are Boosting Retention, Co-CEO Says

20 jan 2026, 22:16 UTC

Acquisities, Fusies, Overnames

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

20 jan 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

20 jan 2026, 22:15 UTC

Acquisities, Fusies, Overnames

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

20 jan 2026, 22:13 UTC

Acquisities, Fusies, Overnames

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

20 jan 2026, 22:11 UTC

Acquisities, Fusies, Overnames

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

20 jan 2026, 22:10 UTC

Acquisities, Fusies, Overnames

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

20 jan 2026, 22:08 UTC

Acquisities, Fusies, Overnames

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

20 jan 2026, 22:07 UTC

Acquisities, Fusies, Overnames

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

20 jan 2026, 22:06 UTC

Winsten

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

20 jan 2026, 22:00 UTC

Marktinformatie
Acquisities, Fusies, Overnames

ESG Roundup: Market Talk

20 jan 2026, 21:50 UTC

Marktinformatie
Winsten

Tech, Media & Telecom Roundup: Market Talk

Smith & Nephew PLC Prognose

Koersdoel

By TipRanks

18.63% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 1,424.1 GBX  18.63%

Hoogste 1,650 GBX

Laagste 958.831 GBX

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Smith & Nephew PLC - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

8 ratings

5

Buy

3

Hold

0

Sell

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Smith & Nephew PLC

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products. It also provides sports medicine joint repair products comprise instruments, technologies, and implants to perform minimally invasive surgery, as well as treating soft tissue injuries and degenerative conditions of the shoulder, knee, hip, and small joints. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg wounds, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, such as biologics and other bioactive technologies for debridement and dermal repair/regeneration, and regenerative medicine products, including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. The company serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
help-icon Live chat